Trak is a software company that specializes in tele-rehabilitation services for healthcare professionals. Its platform allows practitioners to prescribe therapeutic exercises and monitor patients' progress using the cameras on mobile devices, tablets, or laptops. By utilizing artificial intelligence, Trak's software can assess and correct patients' movements and positions in real time, ensuring that the exercises are performed correctly. This innovative approach enables healthcare providers to deliver effective digital treatments, enhancing the quality of care for patients engaged in rehabilitation.
Noah Labs is a technology company focused on developing software-based medical devices for the early detection of cardiovascular diseases through voice analysis. Their innovative digital health platform leverages voice-based machine learning to monitor patients and identify digital biomarkers, facilitating personalized and predictive virtual care. By utilizing this novel technology, Noah Labs aims to enhance patient outcomes, allowing individuals with cardiovascular conditions to lead healthier and longer lives from the comfort of their homes.
Idoven is a pioneering company that has created an innovative cardiology-as-a-service platform utilizing artificial intelligence to enhance the ability of both cardiologists and non-specialist clinicians to identify, triage, and diagnose heart conditions on a large scale. The platform analyzes long-duration electrocardiograms to detect alterations in cardiac electrical activity and arrhythmias, allowing for early diagnosis and prevention of serious cardiac diseases, including myocardial infarction and sudden death. Idoven collaborates with notable partners such as AstraZeneca, Abbott, and Google, and has received investments from prominent firms like Insight Partners and Northzone. The company has been recognized with several prestigious awards for its technology, including accolades from the European Innovation Council and the Healthy Longevity Catalyst Award from the US National Academy of Medicine. Additionally, Idoven has been named one of the top 50 companies in Digital Health by CB Insights for 2023.
eBreathie is a digital health startup that specializes in asthma management through an innovative integrated solution. The company has developed a smart inhaler that monitors both the timing and technique of medication usage, creating detailed inhalation profiles for patients. This device is complemented by a user-friendly mobile app for individuals and a comprehensive management platform for healthcare providers. By leveraging Internet of Things (IoT) technology and artificial intelligence (AI), eBreathie aims to enhance asthma care by providing real-time feedback on inhalation efficacy. This approach seeks to reduce emergency visits, asthma attacks, and hospitalizations, ultimately promoting better patient outcomes and effective inhalation techniques.
Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.
Nanordica Medical is an Estonian medical technology company providing the first-line treatment for chronic wounds based on unique patented nanotechnology, a synergy of copper and silver in nanofibers that remove infection and support wound healing. Nanordica Medical launched a veterinary product Ravimus Vet for animal wounds (https://nanordica.com/ravimus.html) and is developing a first-in-class wound dressing for human hard-to-heal wounds like diabetic foot ulcers. They recently completed a clinical trial showing consistently better results in nearly all efficacy parameters observed among the patients treated with the Nanordica wound dressing than those treated with the commercially available silver ions-based active dressing.
ZiO Health is a biotechnology company that focuses on transforming laboratory testing through its proprietary pocket-sized technology, which allows for point-of-care diagnostics. By combining advanced biosensor technology with machine learning algorithms, ZiO Health provides real-time testing results tailored to each patient's unique profile. This innovative approach enables users to measure, test, and detect the molecular composition of various substances, facilitating personalized health insights. The company's devices aim to optimize health management and enhance patient outcomes, allowing individuals to conduct quality home diagnostics and take proactive steps in preventing illness.
OptiChroniX is a Swiss digital health solution company focused on enhancing brain health through early intervention. The company develops digital health interventions that combine biomedical, behavioral, computing, and engineering research, which are accessible via smartphones. These interventions allow patients to personalize and monitor their brain health by integrating data from various wearables. By offering tailored coaching, OptiChroniX aims to improve health literacy and medication adherence, addressing modifiable risk factors linked to cognitive decline, particularly in patients with Alzheimer’s disease and related co-morbidities. The company's mission is to optimize lifestyle choices and make healthcare more effective, ultimately enhancing clinical outcomes and quality of life.
Onward Assist is an advanced cancer prognostics platform helping Oncologists take better treatment decisions and hence improve outcomes. Onward provides computer vision and ML-based automated diagnostics tools and treatment decision support tools used by Histopathologists, Radiologists, Oncologists. The PathAssist product combines (a) the AI layer with machine learning and computer vision-based tools for automated diagnostics in histopathology, with (b) Pathology workflow/ Telepathology solution as well as (c) a low-cost slide digitisation hardware.
PKVitality is a bio-wearable company based in Paris, France, that specializes in developing innovative health monitoring devices. Its flagship product, K'Watch Glucose, is a smartwatch-style continuous glucose monitoring device that employs a micro-needle sensor to allow diabetics to monitor their glucose levels painlessly and discreetly. This wearable tracker is designed to provide real-time data without the need for calibration, offering a complete history of glucose levels and sending alerts for potential hypo or hyperglycemia episodes. Additionally, PKVitality is expanding its product line to include a Continuous Lactate Monitor and multi-analyte continuous monitors, which will further enhance the capabilities of their health monitoring technology. Founded in 2017, PKVitality aims to simplify health management for individuals, particularly those with diabetes, by eliminating the discomfort associated with traditional blood tests.
dotLumen is a research startup that uses AI, robotics, and neuroscience to empower the blind. dotLumen was founded in 2020 and is headquartered in Cluj, Romania.
dotLumen is a research startup that uses AI, robotics, and neuroscience to empower the blind. dotLumen was founded in 2020 and is headquartered in Cluj, Romania.
NovaBleep is an innovative communications infrastructure layer specifically designed for hospitals. Various modular components are included to replace communication streams such as pagers, referral systems, fault reporting systems, concern escalation systems, ward chats etc. By streamlining and digitalising these essential communication processes, NovaBleep revolutionises the way hospitals operate. The flow of a patient from entering an ED to discharge/death represents the flow of data. Not all of this data is yet digitalised. Data will be aggregated using NovaBleep for use in Machine Learning to predict the trajectory of patients, and to potentially predict mortality.
Orbit Health is a health technology company that specializes in creating an artificial intelligence platform designed for the management of chronic diseases, particularly Parkinson's disease. The platform offers continuous and objective insights into motor symptoms by utilizing smartwatch motion data, which is collected passively without disrupting patients' daily activities. This innovative approach allows physicians to tailor treatments to individual patients, enhancing their ability to achieve optimal symptom control and improving their overall quality of life.
Apneal is a developer of a mobile app that provides a sleep diagnostics platform aimed at assessing sleep quality and diagnosing sleep apnea. By utilizing a smartphone's built-in sensors, including microphones, accelerometers, and gyroscopes, the app can monitor a patient's sleep patterns even in airplane mode, ensuring no electromagnetic interference occurs. The platform employs deep learning technology to transform smartphones into medical devices capable of automatically detecting cardio-respiratory events and analyzing sleep data through interpretable signals. Results are then communicated to healthcare providers via an ergonomic dashboard, allowing users to conduct sleep examinations conveniently without the need for cumbersome equipment or prolonged waiting times.
Lymphatica Medtech SA is a Swiss company focused on designing and manufacturing medical devices for the treatment of lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed LymphoDrain, an innovative medical device that aims to re-establish lymphatic circulation. This system includes an active implantable lymphatic bypass, featuring a magnetically controlled micropump and subcutaneous catheters that facilitate the internal drainage of lymphatic fluid from multiple points within the affected limb. Lymphatica Medtech also produces essential components for LymphoDrain, such as the micropump head and wearable controller, providing a minimally invasive solution for individuals suffering from persistent lymphedema.
Radiobotics focuses on developing advanced machine learning algorithms that assist healthcare professionals in the analysis of medical images, particularly x-rays of bones and joints. By automating the reading of these images, the company's technology streamlines routine tasks and enhances access to radiology reports. This innovation aims to improve diagnostic quality, supporting doctors in making informed medical decisions more efficiently.
Tympany is a platform for performing minimally invasive ear surgeries, reducing unnecessary mastoidectomys and improving outcomes.
Biel Glasses, SL, founded in 2017 and based in Barcelona, Spain, specializes in the development and sale of electronic smart glasses aimed at enhancing mobility and personal autonomy for individuals with low vision. The company’s innovative glasses utilize 3D vision and artificial intelligence algorithms to detect obstacles and environmental changes, translating this information into a format that users can perceive with their remaining vision. Additionally, the glasses feature zoom and image enhancement capabilities, providing a comprehensive solution to support users in navigating their daily lives safely and independently.
Ilya Pharma is a pharmaceutical company focused on developing next-generation biological drugs aimed at enhancing wound healing in skin and mucosa. Founded in 2016 as a spin-out from Uppsala University and the Swedish University of Agriculture, the company employs a unique technique that genetically modifies lactic acid bacteria, commonly found in yogurt. These engineered bacteria serve as vectors to produce and deliver healing substances directly to wounds or within the gastrointestinal tract. This innovative approach is designed to provide accelerated healing for patients, particularly those with diabetes, while maintaining cost-effectiveness.
Allcyte is a biotechnology start-up specializing in functional drug testing using primary human material. The company has developed a high-content imaging platform that analyzes drug action at a single-cell level, closely simulating in vivo conditions. This approach allows for precise evaluation of how cancer treatments may perform in real patients. By employing advanced image analysis and machine learning techniques, Allcyte generates actionable insights that assist physicians and pharmaceutical companies in prioritizing drug development efforts and treatment decisions. The company aims to facilitate personalized medicine for cancer patients, ensuring that the right therapies are matched to the right individuals.
Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform aimed at treating various health conditions, particularly infections and blood-related diseases. Utilizing innovative magnetic blood purification technology, Hemotune's device employs magnetic beads to selectively and efficiently remove large biomolecules from the bloodstream. This approach focuses on addressing the immunological aspects of sepsis, enabling the targeted treatment of multiple disease pathways and improving patient outcomes in acute care settings.
Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.
Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.
HT BioImaging Ltd. specializes in developing innovative medical imaging technology aimed at the early detection of oral cancer. Founded in 2015 and located in Ganei Am, Israel, the company has created the HTOScan, a device that utilizes heat diffusion imaging and artificial intelligence to assess tissue for cancerous characteristics. This technology translates the heat diffusion signals into visual images that indicate the likelihood of cancer, allowing for non-invasive and real-time evaluations at the point of care and in operating rooms. HT BioImaging's approach combines expertise from various fields, including AI, signal analysis, computer vision, and oncology, positioning its platform as a valuable tool for clinicians in community clinics and surgical settings.
Portabiles HealthCare Technologies specializes in high precision solutions for medical gait analysis, focusing on patients with chronic diseases. The company has developed a gait analysis system that employs a validated high-end algorithm to deliver clinical-grade gait parameters derived from everyday activities. This system is accessible to therapists through a telehealth platform or smartphones, providing them with clinically relevant information that can be used to modify or enhance therapy regimes. By offering this innovative technology, Portabiles HealthCare Technologies aims to improve patient monitoring and treatment effectiveness in the realm of rehabilitation.
Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of tissue reconstruction technologies for the reconstructive and plastic surgery markets. It focuses on tissue engineering and has created injectable 3D scaffolds designed to reconstruct soft tissue volumes lost due to tumor ablation, disease, trauma, or for aesthetic reasons. These innovative scaffolds can be injected through thin cannulas, which helps to minimize both intervention and recovery times for patients. Volumina Medical aims to address the challenges associated with the natural repair of soft tissues, offering solutions that enhance surgical outcomes.
Mowoot is a company that specializes in developing non-pharmacological and non-invasive solutions for individuals suffering from chronic constipation. It offers a wearable medical device that delivers an automatic, colon-specific massage, mimicking the manual abdominal massage typically performed by healthcare professionals. Utilizing advanced pneumatic technology, Mowoot's device aims to treat and prevent chronic slow transit constipation without the need for colon cleansing supplements, enemas, or laxatives. Founded in 2014 and based in Barcelona, Spain, Mowoot emerged from the MOEBIO dHEALTH program, which draws inspiration from innovative design and business methodologies. The company's mission is to enhance the quality of life for those affected by chronic constipation through its unique and effective approach.
MRIguidance is a Dutch company that specializes in developing medical imaging software, particularly focused on a technique known as BoneMRI. Founded in 2016 as a spin-off from UMC Utrecht by MR physicist Peter Seevinck, image scientist Marijn van Stralen, and entrepreneur Roel Raatgever, the company has leveraged research dating back to 2013 to create its proprietary technology. The software enables 3D visualization of bone anatomy using conventional magnetic resonance imaging (MRI) scanners, allowing medical practitioners to analyze various human tissues in a single examination without the exposure to harmful radiation. As an UtrechtInc graduate company, MRIguidance aims to enhance medical imaging practices and improve diagnostic capabilities.
Neurent Medical Limited is a medical device company based in Galway, Ireland, founded in 2015. The company focuses on developing innovative solutions for treating rhinitis, including both allergic and non-allergic forms. It offers a single-use, minimally invasive device designed for ENT surgeons that utilizes radio-frequency technology to provide non-surgical interventions for chronic rhinitis. The device is introduced through the nostrils into the nasal cavity under direct endoscopic visualization, where it employs a microelectrode array to deliver targeted energy. This approach interrupts the autonomic function within the mucosal structures of the nasal cavities, effectively reversing the inflammatory process. By enabling treatment in an office setting, Neurent Medical aims to eliminate the complications and costs associated with traditional surgical procedures.
Ancora.ai is an AI-driven digital platform focused on enhancing patient recruitment for clinical trials. By utilizing proprietary generative AI technology, the platform connects patients and healthcare professionals to relevant clinical trials in under five minutes. Ancora.ai emphasizes a patient-first approach, aiming to democratize access to clinical trials and increase participation rates. The platform specifically assists cancer patients by providing personalized treatment plans and ensuring data privacy while facilitating the matching process to suitable clinical research opportunities. This innovative approach seeks to accelerate the recruitment process and improve access to potentially life-saving treatments for patients.
Paragit Solutions specializes in the development of innovative systems for remote patient monitoring and data-driven management of movement disorders, particularly Parkinson's disease. Their flagship product, the Paragit Sleeve, utilizes a patented sEMG (electromyography) technology to capture sensitive data on muscle activation, movement, and grip force during patients' daily activities. Paragit offers two software solutions: the PD Monitor, designed for caregivers to manage Parkinson's disease through data interpretation of key motor symptoms such as rigidity and tremor, and the MD Lab, tailored for decentralized clinical trials across various movement disorders. The PD Monitor provides caregivers with visual data to enhance treatment optimization and telemedicine practices, while the MD Lab enables researchers to analyze over 20 metrics related to disease severity, facilitating comparisons and tracking trends across different patient groups. This integration of hardware and software allows for improved patient care and more efficient clinical research.
BOCAhealth is a patented portable device (connected to an app) that is able to measure and keep track of the hydration status of a user without the need for medical personnel.
Non Equity Assistance in 2020
SCARLETRED is an international digital health scaleup transforming the skincare market with its AI-powered SCARLETRED®VISION platform. The company addresses the challenges of subjective skin assessments and the lack of standardization in dermatology through its certified medical device. The platform operates via a mobile app on smartphones and connects to a web-based system, allowing for the generation of smart imaging data and AI-driven decision support applications in dermatology and telemedicine. This award-winning technology is offered internationally through a Software as a Service (SaaS) model to biopharma companies, the cosmetics industry, hospitals, and medical professionals. Protected by worldwide patents, SCARLETRED facilitates standardized skin documentation and remote tracking of skin changes and treatment effects. Users can upload images to a cloud-based platform for objective analysis of visual skin changes over time, addressing various dermatologic conditions. The company's services cater to a wide range of applications, from B2B to B2B2C.
Vitrue Health focuses on developing digital technology to address musculoskeletal issues through accurate measurement and analysis. Their flagship product, VIDA, is a comprehensive service aimed at reducing problems such as back and neck pain among desk workers by ensuring compliance with ergonomic standards for remote, office, and hybrid environments. Utilizing advanced AI, VIDA assesses workspace quality and empowers employees with knowledge to improve their environments, thereby enhancing their overall well-being. Additionally, Vitrue's EVVA technology employs depth sensors for clinical-grade assessments in orthopaedics and injury prevention, offering precise evaluations of functional movements throughout rehabilitation. By leveraging computer vision and biomechanics, Vitrue Health not only collects and analyzes health data but also provides actionable insights to both clinicians and patients, promoting early detection of issues and informed decision-making in treatment plans. Their mission is to transform musculoskeletal healthcare and significantly reduce pain for millions of individuals.
Pharma Latch, a subsidiary of Latch Medical, specializes in innovative drug and vaccine delivery systems that utilize advanced microneedle technology. This approach allows for intradermal delivery, meaning that medications can be administered directly into the skin, enhancing patient comfort and experience. The company has developed a tissue anchor system featuring opposing arrays of angled microneedles, which painlessly penetrate the skin while ensuring consistent delivery depth. This technology aims to improve the effectiveness of drug and vaccine administration and provides healthcare professionals with better alternatives for wound management. Through its core platform technology, Pharma Latch is positioned to make significant advancements in the field of medical delivery systems.
Waytob specializes in developing assistive technology solutions designed to enhance the mobility of individuals with special educational needs. Their innovative navigation application offers intuitive, icon-based directions on a smartwatch, allowing users to navigate outdoor environments safely and independently. The technology not only guides users by indicating safe crossing points but also enables family members to monitor their loved ones' location, heart rate, and battery life. By prioritizing accessibility, Waytob aims to empower those with higher support needs to travel confidently while providing reassurance to their caregivers.
AquAffirm specializes in creating innovative digital solutions for environmental and public health challenges. The company has developed a user-friendly web-based tool that utilizes sophisticated models to analyze epidemic trajectories and manage restrictions related to COVID-19, making advanced prediction capabilities accessible to small businesses and developing countries. Additionally, AquAffirm designs digital sensors that detect serious water contaminants such as arsenic and fluoride. These sensors are equipped with advanced mapping and infrastructure modeling tools, enabling the creation of detailed three-dimensional models of water infrastructure. By integrating real-time optimization functionalities, AquAffirm's solutions help clients effectively address pressing biomedical and environmental issues.
BeneTalk is a digital speech therapy application designed to assist individuals who stutter in communicating more confidently and comfortably. The app functions similarly to a fitness tracker, enabling users to learn and practice new speaking habits during everyday conversations. It monitors key aspects of speech, such as breathing and speech patterns, while providing real-time feedback and tracking performance history. This feature aims to enhance the quality of life for individuals who stutter and their families by helping them address speech and language difficulties effectively.
Novus Diagnostics is focused on developing an innovative diagnostic device that addresses sepsis, a life-threatening condition caused by infections. The company's technology enables rapid detection and classification of pathogens directly from whole blood samples. By providing quick and automated pathogen identification in just minutes, Novus Diagnostics aims to enhance the ability of healthcare providers to treat patients efficiently and effectively, while also maintaining cost-effectiveness in the diagnostic process.
uFraction8 provides scalable bioprocessing technology enabling biomass filtration, separation and dewatering, used with wide range of microbes like micro algae, yeast and bacteria, sorting biomass from culture medium with no harm and no flocculants unlike centrifuges, filters and membranes.
neoMimix allows for natural sperm selection for assisted human reproduction. The solution provides the most natural, ex-vivo, biomimicry of the female reproductive tract for sorting and selecting the highest grade, lowest DNA fragmented sperm in a simple and fully traceable process.
Hygiene Audits offers a software solution for infection prevention and control in nursing homes by providing automated workflows for care staff, tracking and tracing infection risks, and helping reduce healthcare-associated infections.
Capbuster is a balloon catheter & guidewire combination device, that provides Physicians with an easy-to-use and innovative solution. It will be used to re-open the most resistant occlusions where a calcified cap has formed on the surface of the blockage.CapBuster uses the mechanical advantage of a screw-thread and uses standard tools and techniques used in all angioplasties in every hospital cath lab in the world. It provides a simple, fast, cost-effective, low-risk method with a high degree of penetration through the calcified blockage to treat CTO’s with minimal training required for the Physician and no capital equipment required for the hospital.
Oxolife is a biotechnology startup established in January 2013, specializing in research and development of reproductive efficiency and infertility treatments. Founded by a multidisciplinary team of biochemists and clinical pharmacologists with over a decade of experience in research and development, Oxolife focuses on improving female fertility. The company's innovative drug targets the endometrium to enhance embryo implantation and restore ovulation, aiming to simplify the fertility treatment process for infertile women and couples.
KroniKare AI-based system helps with early detection of complications such as infection, undermining and blood circulation problems. This can significantly reduce costs for chronic wound care from faster recovery of patients to productivity gains and upskilling of junior nurses.
BioXplor, Inc. is a research and development company based in Berkeley, California, established in 2017. It specializes in an augmented intelligence platform that facilitates data-driven hypothesis generation and novel predictions in biomarker and drug discovery. The platform integrates big data, artificial intelligence, and high-performance computing to enhance data interpretation from both unstructured literature and structured multi-omics data. BioXplor focuses on AI-assisted biomarker discovery, molecular target identification, and drug repurposing, with ongoing projects primarily aimed at cancer and rare diseases.
Vinehealth develops a digital application focused on enhancing oncology patient outcomes through the integration of data science and behavioral science. This patient-centric technology allows individuals battling cancer to effectively track, manage, and comprehend their treatment journey. By utilizing behavioral science principles, Vinehealth's application generates valuable patient-reported data, which can inform healthcare delivery, drug development, and research. This personalized support not only aids patients but also equips clinicians with a comprehensive understanding of patient experiences, facilitating tailored healthcare services.
CrannMed is a medical company focused on addressing the challenges of knee osteoarthritis, a condition that causes chronic pain and limits mobility. The company is developing innovative solutions that include bioresorbable embolic particles and a specialized balloon occlusion microcatheter. These products are designed to provide an alternative treatment option for patients, allowing for minimally invasive procedures that aim to improve patient outcomes and halt disease progression. By targeting the growing particle embolization market, CrannMed seeks to enhance the quality of life for individuals suffering from this debilitating condition.
Upstream Health, founded in 2018 and based in North Lincolnshire, United Kingdom, specializes in developing innovative technologies and service approaches for health and social care teams. The company leverages artificial intelligence alongside a mobile and analytics platform to promote a preventive care model. By focusing on an "upstream" strategy, Upstream Health aims to enhance citizen outcomes and improve patient care through its electronic medical record innovation technology. The team comprises experienced technologists and health service innovators dedicated to addressing the evolving needs of the health and social care systems.
SurgiQ is an AI-driven healthcare technology company that specializes in optimizing hospital operations, particularly in the areas of surgical procedures, chemotherapy, and rehabilitation. By providing intelligent planning and scheduling solutions, SurgiQ assists hospitals in streamlining workflows, reducing waiting times, and maximizing resource efficiency. Its patented AI technology facilitates balanced workloads and enhances patient care while also contributing to improved financial performance for healthcare institutions. The company caters to both public and private healthcare facilities, offering a scalable solution that delivers measurable results. SurgiQ is experiencing significant growth and is preparing to expand its reach internationally.
Oncochain is focused on creating a real-world data platform tailored for oncology, aimed at standardizing and aggregating anonymized data from cancer patients. This platform generates valuable analytics that support pharmaceutical research and enhance value-based care for healthcare providers. Utilizing a web-based oncology-specific electronic health record, Oncochain develops operational data repositories that streamline the information flow between providers and enhance the skills of oncology professionals. The platform significantly aids research by reducing the time required for patient recruitment in clinical trials and establishing a framework for multi-centric study design and implementation. Through its SaaS analytics tool, Oncochain provides critical real-world data insights to clients, including pharmaceutical companies and contract research organizations, ultimately contributing to improved outcomes in oncological care and accelerating research efforts.
I'm Fine is a mobile app that offers psychological support via a web platform. They provide resources and tools to help better understand their emotions, such as personalized mood recommendations and referrals to vetted psychotherapists. The psychologist platform allows them to track their client's progress and assign them tasks to help them improve their therapeutic outcomes.
Biel Glasses, SL, founded in 2017 and based in Barcelona, Spain, specializes in the development and sale of electronic smart glasses aimed at enhancing mobility and personal autonomy for individuals with low vision. The company’s innovative glasses utilize 3D vision and artificial intelligence algorithms to detect obstacles and environmental changes, translating this information into a format that users can perceive with their remaining vision. Additionally, the glasses feature zoom and image enhancement capabilities, providing a comprehensive solution to support users in navigating their daily lives safely and independently.
SentinHealth is a life science company that specializes in developing integrated care solutions aimed at tracking and preventing the progression of chronic illnesses. The company focuses on telemonitoring technology, which includes an implant connected to the cloud that provides daily health status updates and predictive information. This innovative approach is particularly beneficial for patients with serious chronic conditions, as it allows for early detection of health issues, such as acute decompensated heart failure (ADHF), before they require emergency care. By addressing the critical need for continuous monitoring in patients, SentinHealth aims to improve health outcomes and reduce the demand for acute medical interventions.
ABLE Human Motion is a Barcelona-based medical device start-up founded in 2018 that specializes in the development of robotic exoskeletons designed to improve mobility for individuals with disabilities. The company's primary product, the ABLE Exoskeleton, is a lightweight and user-friendly wearable device that assists paraplegic users in standing, walking, and sitting. This innovative technology employs a motor and gearbox to mimic muscle movement, along with an inertial sensor to interpret the user's intentions. ABLE Human Motion aims to enhance the quality of life for wheelchair users by promoting greater independence and mobility while also providing rehabilitation tools for clinicians to improve treatment efficiency.
Menutech, a B2B SaaS company, is changing the foodservice technology market by bringing AI-powered menu planning personalisation for F&B managers, dieticians and nursing staff. Our customers automise the creation of meal plans that are personalised to the individual dietary requirements of their patients and guests. Menutech reduces health risks and over procurement costs for hospitals, senior homes and hospitality businesses by reducing the time to prepare personalised meal plans by up to 90%.
Sleepiz AG, based in Zurich, Switzerland, specializes in manufacturing a non-contact sleep monitoring device aimed at enhancing healthcare accessibility in home environments. Incorporated in 2018, the company's innovative product is designed to be placed on a bedside table, where it accurately measures patients' breathing patterns, heart rate, and body movements using advanced wireless millimeter wave technology and artificial intelligence. This device not only facilitates the diagnosis of sleep disorders but also enables long-term monitoring of chronic diseases, allowing healthcare providers to track patient progression and implement timely interventions for improved treatment outcomes. Through its user-friendly and precise approach, Sleepiz is positioned to significantly contribute to patient-centric disease management.
Pipra is a MedTech start-up focused on addressing the significant issue of delirium in healthcare, particularly Post-Operative Delirium (POD), which affects around 20% of patients over 60 and incurs substantial costs for hospitals and insurers. The company has developed an AI-driven clinical decision support software that enables healthcare professionals to identify high-risk patients prior to surgery. This pre-operative risk assessment tool utilizes standard medical data and can be accessed via web or app, providing a score-based risk assessment in under two minutes. By highlighting patients at risk, Pipra's solution allows for the implementation of targeted interventions that have been shown to reduce the incidence of POD by 53%. Currently, Pipra's technology is operational in three hospitals, with plans for deployment in an additional 22 hospitals across Europe. The company's advisory board includes experts from renowned institutions such as Johns Hopkins, Harvard, and Cornell, further enhancing its credibility in the field.
iLoF, or Intelligent Lab on Fiber, is a developer of a digital health platform that utilizes advanced photonics and artificial intelligence to enhance personalized drug discovery and development. The company has created a patented system that identifies and captures unique features of gold-standard biomarkers, compiling this information into a cloud-based library. By leveraging this extensive database, iLoF aims to facilitate collaboration among physicists, biologists, and data scientists, ultimately improving the efficiency and patient-centricity of clinical trials. This innovative approach not only reduces the costs associated with drug development but also aims to provide patients with tailored, life-saving treatments.
The Oxford Foundry is an entrepreneurial growth center located within the University of Oxford, established in 2017. It serves as an accelerator firm dedicated to supporting venture creation and growth while harnessing talent to address global challenges. The Foundry offers a variety of resources, including masterclasses, access to a network of industry experts, mentors, and advisors, as well as grant funding. Additionally, it provides assistance with legal and financial guidance and offers co-working space through its accelerator program.
TeiaCare is a health technology company focused on enhancing care in long-term care facilities through the use of artificial intelligence. Their primary solution, ANCELIA, automates the collection and analysis of resident data to improve management and care delivery. By generating smart alerts, reminders, and comprehensive reports, TeiaCare helps nursing homes optimize the monitoring of post-acute hospital patients, thereby addressing inefficiencies in care. The aim is to empower healthcare workers and managers, allowing them to extend high-quality assistance to more residents without increasing workload. TeiaCare's approach emphasizes personalized care, objective data analysis, and transparency, ultimately driving a new model of assistance that enhances the quality of life for residents while streamlining operational processes for care providers.
BeSure Online is a digital platform for daily aging patients’ monitoring, stroke risk mitigation, clinical decision support, and health plans optimization. Using data from wearable devices, IoT and medical equipment, as well as external data, BeSure makes real-time analysis of leading health indicators in order to predict the onset of emergent situations and evaluate health outcomes Precise COVID19: remote patients monitoring and clinical decision support system for healthcare providers with coronavirus COVID-19 patients
Sleepiz AG, based in Zurich, Switzerland, specializes in manufacturing a non-contact sleep monitoring device aimed at enhancing healthcare accessibility in home environments. Incorporated in 2018, the company's innovative product is designed to be placed on a bedside table, where it accurately measures patients' breathing patterns, heart rate, and body movements using advanced wireless millimeter wave technology and artificial intelligence. This device not only facilitates the diagnosis of sleep disorders but also enables long-term monitoring of chronic diseases, allowing healthcare providers to track patient progression and implement timely interventions for improved treatment outcomes. Through its user-friendly and precise approach, Sleepiz is positioned to significantly contribute to patient-centric disease management.
Smiletronix is a dental health technology company that offers a home dental check-up and teledentistry solution. Utilizing a patented intra-oral imaging device, along with an app powered by artificial intelligence, the system enables users to perform dental health scans in under a minute from the comfort of their homes. This innovative approach allows individuals to monitor their dental health for issues such as cavities, gum disease, plaque, and tooth erosion. By shifting dental care from a reactive to a preventive model, Smiletronix aims to reduce pain and costs while making dental care more convenient and accessible. The company's solutions not only promote better long-term health for patients but also lead to significant savings for healthcare payers.
BrachyDOSE is the game changing cancer treatment quality control tool to empower oncology doctors to provide 100% accurate and error free radiotherapy treatment. Solution solves a problem touching 200 mln patients World Wide and +2000 hospitals in both Europe and the USA. This is a new approach of combining hardware dose measurement tool with deep learning algorithms to provide high accuracy data. It will help to reduce overall treatment costs per patient by 3-5 times, to saves up to 50% of doctors' and medical specialists' time for procedure preparation and will help cancer patient to came back to normal life sooner. BrachyDOSE solution consists of two parts: hardware and software. The radiation dose measurement tool – called sensor (hardware), a scanner to retrieve the data (hardware) and the injury prediction algorithm giving the decision support for a doctor (software). The sensor is in a shape of the flexible tube, it is disposable and at least one must be used during the procedure. One to five sensors could be used for a single procedure, according to the doctor’s prescription and the specific treatment plan.
Ergobyte Informatics S.A. is a software development company based in Thessaloniki, Greece, founded by George Nikolaidis in 2002. The company specializes in creating commercial products and services, alongside custom application development tailored to client needs. Ergobyte conducts research in various fields of information and communication technology, including computer-aided diagnosis, knowledge representation, machine learning, and data analytics. It develops off-the-shelf software products and information systems primarily for the medical sector, with Galen, an online drug database focused on human pharmacology, being one of its notable offerings. Additionally, Ergobyte designs applications for smartphones and portable devices, ensuring compatibility with both iPhone and Android platforms.
Biel Glasses, SL, founded in 2017 and based in Barcelona, Spain, specializes in the development and sale of electronic smart glasses aimed at enhancing mobility and personal autonomy for individuals with low vision. The company’s innovative glasses utilize 3D vision and artificial intelligence algorithms to detect obstacles and environmental changes, translating this information into a format that users can perceive with their remaining vision. Additionally, the glasses feature zoom and image enhancement capabilities, providing a comprehensive solution to support users in navigating their daily lives safely and independently.
Sleepiz AG, based in Zurich, Switzerland, specializes in manufacturing a non-contact sleep monitoring device aimed at enhancing healthcare accessibility in home environments. Incorporated in 2018, the company's innovative product is designed to be placed on a bedside table, where it accurately measures patients' breathing patterns, heart rate, and body movements using advanced wireless millimeter wave technology and artificial intelligence. This device not only facilitates the diagnosis of sleep disorders but also enables long-term monitoring of chronic diseases, allowing healthcare providers to track patient progression and implement timely interventions for improved treatment outcomes. Through its user-friendly and precise approach, Sleepiz is positioned to significantly contribute to patient-centric disease management.
Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, specializing in the development of a metabolism-based liquid biopsy platform aimed at the early detection and monitoring of cancer. Founded in 2017, the company focuses on measuring biomarkers in blood and urine, employing machine learning and artificial intelligence algorithms to identify cancer signatures. Elypta is actively conducting the AURORAX clinical trial series to explore applications for its platform, particularly in renal cell carcinoma, while also investigating other cancer indications. The technology includes a new in vitro diagnostic laboratory assay kit, which enables comprehensive profiling of glycosaminoglycan metabolites and supports a range of applications from screening to treatment response monitoring, facilitating earlier interventions in cancer care.
TeiaCare is a health technology company focused on enhancing care in long-term care facilities through the use of artificial intelligence. Their primary solution, ANCELIA, automates the collection and analysis of resident data to improve management and care delivery. By generating smart alerts, reminders, and comprehensive reports, TeiaCare helps nursing homes optimize the monitoring of post-acute hospital patients, thereby addressing inefficiencies in care. The aim is to empower healthcare workers and managers, allowing them to extend high-quality assistance to more residents without increasing workload. TeiaCare's approach emphasizes personalized care, objective data analysis, and transparency, ultimately driving a new model of assistance that enhances the quality of life for residents while streamlining operational processes for care providers.
ABLE Human Motion is a Barcelona-based medical device start-up founded in 2018 that specializes in the development of robotic exoskeletons designed to improve mobility for individuals with disabilities. The company's primary product, the ABLE Exoskeleton, is a lightweight and user-friendly wearable device that assists paraplegic users in standing, walking, and sitting. This innovative technology employs a motor and gearbox to mimic muscle movement, along with an inertial sensor to interpret the user's intentions. ABLE Human Motion aims to enhance the quality of life for wheelchair users by promoting greater independence and mobility while also providing rehabilitation tools for clinicians to improve treatment efficiency.
Abtrace specializes in AI-based solutions designed to enhance medical expertise and streamline healthcare processes. The company focuses on developing clinical decision-making tools that transform the detection, monitoring, and treatment of chronic and long-term health conditions. By utilizing machine learning and big data techniques, Abtrace's software analyzes patient data to provide insights that help healthcare professionals manage current diseases and identify early signs of new conditions. This approach not only improves patient safety but also reduces the misuse of antibiotics and enhances treatment outcomes. Additionally, Abtrace's solutions automate key aspects of disease monitoring, enabling general practitioners and healthcare assistants to make informed decisions and deliver effective care while lowering practice costs and saving time.
RemAb Therapeutics is a developer of polymeric glycoconjugates molecule designed to remove antibodies and treat nosocomial infections. The company's technology aims to develop polymeric glycoconjugates to eliminate non-neutralizing natural antibodies that interfere with the natural response of the immune system and favor pathogen growth, providing patients with a new way of treating and preventing various pathologies.
SensArs is a medical equipment manufacturing company specializing in neuromodulation technology aimed at treating diabetic neuropathy. The company has developed an innovative implantable neurostimulator electrode designed to restore sensory feedback by delivering precise electrical impulses to the nerve fibers that transmit pain signals. This technology not only assists healthcare providers in enhancing patient functionality but also offers a long-term solution for pain management. SensArs' flagship system, SENSY, is particularly beneficial for patients with amputations or nerve damage, as it helps to restore natural sensations in their feet.
STENTiT is a medical device company that emerged from the Eindhoven University of Technology in the Netherlands, specializing in regenerative endovascular implants. The company develops biodegradable stents aimed at restoring arteries by promoting a natural healing response. These implants facilitate the circulation of blood cells that replace the stent with new vascular tissue, effectively restoring the artery from within. This innovative approach enables healthcare professionals to treat patients suffering from cardiovascular diseases more effectively.
Nanoleq AG, established in 2017 and based in Zurich, Switzerland, specializes in the development and manufacturing of innovative electric cables using stretchable electronics. As a spinoff from ETH Zurich, the company focuses on integrating electronic functionalities into textiles, particularly for health monitoring. Its products utilize advanced conductive silicone technology to create soft sensors capable of recording vital signs such as heartbeat, electrocardiograms, and breathing patterns through comfortable and washable garments. These sensors are designed for various applications, including healthcare, sports, and workwear, with the aim of setting a standard in the health-monitoring textile market. Nanoleq is committed to facilitating the rapid development and widespread adoption of smart textiles across multiple sectors, including robotics and aerospace.
Sleepiz AG, based in Zurich, Switzerland, specializes in manufacturing a non-contact sleep monitoring device aimed at enhancing healthcare accessibility in home environments. Incorporated in 2018, the company's innovative product is designed to be placed on a bedside table, where it accurately measures patients' breathing patterns, heart rate, and body movements using advanced wireless millimeter wave technology and artificial intelligence. This device not only facilitates the diagnosis of sleep disorders but also enables long-term monitoring of chronic diseases, allowing healthcare providers to track patient progression and implement timely interventions for improved treatment outcomes. Through its user-friendly and precise approach, Sleepiz is positioned to significantly contribute to patient-centric disease management.
TeiaCare is a health technology company focused on enhancing care in long-term care facilities through the use of artificial intelligence. Their primary solution, ANCELIA, automates the collection and analysis of resident data to improve management and care delivery. By generating smart alerts, reminders, and comprehensive reports, TeiaCare helps nursing homes optimize the monitoring of post-acute hospital patients, thereby addressing inefficiencies in care. The aim is to empower healthcare workers and managers, allowing them to extend high-quality assistance to more residents without increasing workload. TeiaCare's approach emphasizes personalized care, objective data analysis, and transparency, ultimately driving a new model of assistance that enhances the quality of life for residents while streamlining operational processes for care providers.
Biel Glasses, SL, founded in 2017 and based in Barcelona, Spain, specializes in the development and sale of electronic smart glasses aimed at enhancing mobility and personal autonomy for individuals with low vision. The company’s innovative glasses utilize 3D vision and artificial intelligence algorithms to detect obstacles and environmental changes, translating this information into a format that users can perceive with their remaining vision. Additionally, the glasses feature zoom and image enhancement capabilities, providing a comprehensive solution to support users in navigating their daily lives safely and independently.
GlyCardial Diagnostics S.L., established in 2017 and based in Barcelona, Spain, is a biotechnology company that focuses on developing innovative diagnostic solutions for cardiovascular health. The company specializes in a point-of-care device designed to detect abnormal levels of the Apo J-Glyc protein in the blood, which serves as a biomarker for the early diagnosis of cardiac ischemia. This technology aims to identify patients at risk of recurrent cardiovascular events and facilitate timely healthcare decisions to prevent irreversible myocardial damage and heart failure. As a spin-off from the Catalan Institute of Cardiovascular Sciences and the Spanish National Research Council, GlyCardial Diagnostics addresses critical unmet medical needs in the field of cardiology.
Delox, founded in 2018 and based in Cascais, Portugal, specializes in the design and development of bio-decontamination devices aimed at creating clean and safe environments. As a spin-off from the Faculty of Sciences of the University of Lisbon, the company has developed innovative technologies, including DeloxHP, a solid formulation that safely releases concentrated hydrogen peroxide vapor. This advancement allows for the creation of compact and cost-effective bio-decontamination solutions, such as the Delox Box. Delox's applications span various sectors, including the sterilization of medical devices, bio-decontamination of laboratory equipment, and room decontamination in hospitals, the food industry, and even space environments. The company focuses on providing non-toxic solutions to combat microorganisms, ensuring safe handling and transportation of hydrogen peroxide through its cartridge system.
Adelie Health is an app that helps people with diabetes manage their insulin doses.
Inovus Ltd is a company based in Saint Helens, United Kingdom, that specializes in designing and manufacturing medical simulation products aimed at enhancing surgical training. Founded in 2012, the company offers a variety of simulators, including take-home laparoscopic simulators and institutional models, which focus on essential surgical techniques such as laparoscopic appendectomy and cholecystectomy. Inovus Ltd's products are tailored for surgical trainees and residents, providing them with accessible and versatile training options that improve their skills in critical care, medicine, and surgery. The company's commitment to advancing surgical education enables clinicians to deliver better patient care through improved training resources.
Non Equity Assistance in 2018
We develop a new PET scanner technology that reduces costs significantly, enabling a wider use of PET by research, training and diagnostic imaging centers. Our mission is to increase access to PET imaging around the world, by providing uniquely affordable, high resolution compact systems. Our motto: keep PET simple!
Onalabs develops remote, continuous and non-invasive bio-medical devices to monitor through the skin and sweat several vital signs and some biomarkers. Onalabs is the first non-invasive device able to measure some chemical parameters present in sweat using miniaturised biosensors. Its non-invasive products based on wearable formats empower the patients and their families to measure relevant vital signs and biomarkers anytime and anywhere, allowing them to detect and monitor early stages of possible clinical deterioration, which could prelude in earlier management strategies, resulting in shorter hospital stays and prevention of unnecessary treatments. The solutions are addressed to chronic patients, such as COPD, HF and Diabetes.
Climedo, founded in Munich in 2017, specializes in a clinical data collection platform that supports non-interventional studies and real-world evidence through a patient-centric approach. The platform integrates electronic Clinical Outcome Assessments (eCOA) and Electronic Data Capture (EDC) capabilities, allowing for the collection and analysis of medical research data in real time. By providing structured data storage and visualizations of study progress, Climedo enhances engagement between clients, healthcare professionals, and key opinion leaders, promoting scientific dialogue and increasing the likelihood of successful product launches. With over 1.7 million patients enrolled, Climedo serves as a valuable partner for pharmaceutical companies, medical technology firms, contract research organizations, and academic institutions, facilitating data-driven treatments and efficient validation of medical innovations.
We believe that good care is not a privilege. That is why we have developed intelligent solutions under the nevisCura brand that significantly improve the living and working situation of people in the care sector. Our technical assistance systems have been specially developed for care facilities to offer them a cost-effective and efficient solution for more relief and security. In doing so, we have never lost sight of the customer focus and have incorporated the feedback from numerous pilot projects with long-standing customers into the further development. Only in this way could we be sure that our solutions supported caregivers in their everyday work and relieved them in the long term. And that for many years: because the solutions are designed to be future-proof so that you benefit from regular updates and the highest level of investment protection. Our solution consists of the nevisCura bed and room sensor. The bed sensor from nevisCura is an intelligent bed exit alarm that noticeably facilitates the daily work of caregivers. Once attached to the bed in just a few steps, the silent guard discreetly signals when a resident wants to get out of bed - even before he or she has set foot on the floor. And best of all: the sensor is compatible with every common call system. The room sensor from nevisCura is an innovative sensor system that is used for fall detection and prevention in outpatient and inpatient care facilities. Once installed all around at the height of the base boards, it offers the greatest protection for residents and noticeably relieves caregivers.
Oxford Heartbeat develops innovative medical device software designed to enhance the planning and execution of cardiovascular surgeries. The company's platform allows surgeons to visualize critical information about a patient's anatomy by providing insights into blood vessels, tissue, and bone structures. This advanced technology, which leverages predictive computations, big data, and artificial intelligence, enables medical professionals to rehearse procedures and select the most effective surgical scenarios tailored to individual patients. By improving surgical preparation, Oxford Heartbeat aims to reduce complication rates and associated healthcare costs while enhancing overall patient care. The company is currently conducting prospective clinical trials in NHS hospitals, supported by the UK government's AI in Health and Care Awards.
2Eyes Vision S.L, founded in 2015 and based in Madrid, Spain, specializes in developing technology for visual diagnostics and corrections. The company has created SimVis, a proprietary visual simulation technology specifically designed for multifocal lens applications in presbyopia and cataract surgery. This technology allows patients to experience real-world vision prior to undergoing surgical procedures, addressing the challenge faced by surgeons in selecting the most suitable intraocular lenses from a vast array of options available in the market. The SimVis Gekko device, which has received FDA clearance and CE marking, is portable and user-friendly, enhancing patient satisfaction and assisting ophthalmologists in making informed decisions about lens selection. With over 2 billion people globally affected by presbyopia and cataracts, and an aging population contributing to increased surgical options, 2Eyes Vision aims to improve clinical practices and patient outcomes in the field of ophthalmology.
Onalabs develops remote, continuous and non-invasive bio-medical devices to monitor through the skin and sweat several vital signs and some biomarkers. Onalabs is the first non-invasive device able to measure some chemical parameters present in sweat using miniaturised biosensors. Its non-invasive products based on wearable formats empower the patients and their families to measure relevant vital signs and biomarkers anytime and anywhere, allowing them to detect and monitor early stages of possible clinical deterioration, which could prelude in earlier management strategies, resulting in shorter hospital stays and prevention of unnecessary treatments. The solutions are addressed to chronic patients, such as COPD, HF and Diabetes.
Aelix Therapeutics develops therapeutic vaccines and immunotherapies to treat HIV infection. The company is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was created under the leadership of its founders, Dr. Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Mr. Jordi Naval; all of whom have several decades of experience in HIV and biotech development. The company’s know-how will further expand through unique immunogen designs. It will also benefit from ready access to large cohorts of HIV infected patients in several continents through its partnership with the HIVACAT consortium.
Rethink Medical is a medical company that aims to develop innovative medical solutions to various health problems. This includes creating new remedies or significantly improving existing ones. The first product is the T-Control Urinary Catheter. It
AVX Pharma is a biopharmaceutical company focused on developing novel drugs addressing major ophthalmic unmet medical needs, with especial focus on ocular surface diseases. The company was founded in July 2013 on the grounds of neurobiological research performed by the Group on Ocular Sensory Innervation led by Prof. Carlos Belmonte at the Instituto de Neurociencias de Alicante, and its operations are carried from Barcelona.
MetaHeps GmbH provides consulting and solutions for drug-induced liver injury (DILI) in clinical drug-development and postmarketing. It is a unique service provider that generates a personalized cell model reflecting individual drug hepatotoxicity from a small patient blood sample. Customers are research driven pharmaceutical companies and global acting CROs, using Metaheps’ services in clinical phases of drug development as well as postmarketing to diagnose or exclude Druginduced liver injury (DILI) in individual patients. MetaHeps vision is to increase access of patients to novel drugs by addressing DILI issues in drug development in an unrivaled and innovative approach.
NUA Surgical is an innovative start-up located at the Innovation Hub in Galway, Ireland, focused on enhancing women's health through advanced medical devices. The company has developed a patented surgical retractor specifically designed to improve the safety and efficiency of cesarean deliveries. By concentrating on research and development, NUA Surgical aims to provide obstetricians with tools that facilitate superior surgical outcomes, ultimately making C-sections safer for patients.